I-Mab (IMAB) Competitors $2.25 -0.09 (-4.02%) Closing price 03:59 PM EasternExtended Trading$2.29 +0.04 (+1.91%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMAB vs. SNDX, CMRX, CDMO, ORIC, QURE, AVXL, IMNM, GYRE, PHAT, and VIRShould you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include Syndax Pharmaceuticals (SNDX), Chimerix (CMRX), Avid Bioservices (CDMO), Oric Pharmaceuticals (ORIC), uniQure (QURE), Anavex Life Sciences (AVXL), Immunome (IMNM), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry. I-Mab vs. Its Competitors Syndax Pharmaceuticals Chimerix Avid Bioservices Oric Pharmaceuticals uniQure Anavex Life Sciences Immunome Gyre Therapeutics Phathom Pharmaceuticals Vir Biotechnology I-Mab (NASDAQ:IMAB) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Do analysts rate IMAB or SNDX? I-Mab currently has a consensus target price of $6.00, indicating a potential upside of 167.14%. Syndax Pharmaceuticals has a consensus target price of $35.80, indicating a potential upside of 296.72%. Given Syndax Pharmaceuticals' higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than I-Mab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score I-Mab 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Which has more risk and volatility, IMAB or SNDX? I-Mab has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Do insiders and institutionals have more ownership in IMAB or SNDX? 38.4% of I-Mab shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is IMAB or SNDX more profitable? I-Mab has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -757.53%. I-Mab's return on equity of -19.81% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets I-MabN/A -19.81% -18.63% Syndax Pharmaceuticals -757.53%-101.60%-58.41% Which has preferable valuation & earnings, IMAB or SNDX? I-Mab has higher earnings, but lower revenue than Syndax Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioI-Mab$3.89M47.15-$22.23MN/AN/ASyndax Pharmaceuticals$23.68M32.79-$318.76M-$3.86-2.34 Does the media prefer IMAB or SNDX? In the previous week, I-Mab had 2 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 7 mentions for I-Mab and 5 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.38 beat I-Mab's score of 0.31 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Syndax Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryI-Mab beats Syndax Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAB vs. The Competition Export to ExcelMetricI-MabMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$183.41M$2.90B$5.49B$8.93BDividend YieldN/A2.69%5.38%4.12%P/E RatioN/A21.2626.2019.89Price / Sales47.15279.34415.50166.23Price / CashN/A41.8936.4957.06Price / Book0.917.508.055.39Net Income-$22.23M-$55.05M$3.15B$248.50M7 Day Performance-19.21%2.49%1.92%2.96%1 Month Performance75.47%7.40%4.90%6.02%1 Year Performance42.15%5.42%35.95%20.44% I-Mab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMABI-Mab3.0453 of 5 stars$2.25-4.0%$6.00+167.1%+44.4%$183.41M$3.89M0.00380News CoverageSNDXSyndax Pharmaceuticals3.0879 of 5 stars$9.19-3.1%$35.91+290.7%-59.0%$815.73M$23.68M-2.38110CMRXChimerix0.6761 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.9093 of 5 stars$12.50+0.1%$12.25-2.0%+75.5%$799.18M$139.91M-5.23320High Trading VolumeORICOric Pharmaceuticals4.1851 of 5 stars$10.00+7.4%$19.17+91.7%+32.7%$793.44MN/A-5.3580QUREuniQure2.0406 of 5 stars$13.95-1.8%$37.82+171.1%+214.7%$778.36M$27.12M-3.18500News CoverageAVXLAnavex Life Sciences3.9009 of 5 stars$9.30+2.3%$44.00+373.1%+127.0%$776.03MN/A-16.9140Positive NewsIMNMImmunome2.4624 of 5 stars$8.74-0.1%$23.33+167.0%-30.6%$761.36M$10.94M-2.7540Positive NewsGYREGyre Therapeutics0.2919 of 5 stars$7.77-3.7%N/A-38.0%$756.62M$105.76M388.6940PHATPhathom Pharmaceuticals4.04 of 5 stars$9.47-9.1%$17.50+84.8%-18.1%$727.46M$55.25M-1.81110High Trading VolumeVIRVir Biotechnology3.4319 of 5 stars$5.05-3.4%$32.86+550.6%-43.8%$722.98M$74.21M-1.20580Positive News Related Companies and Tools Related Companies Syndax Pharmaceuticals Alternatives Chimerix Alternatives Avid Bioservices Alternatives Oric Pharmaceuticals Alternatives uniQure Alternatives Anavex Life Sciences Alternatives Immunome Alternatives Gyre Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Vir Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMAB) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
